Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies

Launched by NATIONAL CANCER INSTITUTE (NCI) · Dec 1, 2018

Keywords

ClinConnect Summary

Background:

Increased understanding of the genomic variations of cancer through laboratory evaluations can result in breakthroughs in treatment and improved patient outcomes.

Exceptional responders on clinical trials may have mutational characteristics that are unique and unknown, necessitating identification.

Current drug development strategies employ precision oncology. This approach identifies molecular targets, with therapies being either chosen or developed to interact with the specific target.

The collection and banking of a variety of tissue samples for future translational studi...

Gender

ALL

Eligibility criteria

• * INCLUSION CRITERIA:
• • Adult subject (age 18 and older) co-enrolled on a trial, or otherwise undergoing consultation, screening, or follow up on existing protocols conducted at the NIH Clinical Center, who are evaluated in the Women s Malignancies Branch Clinic.
• * Participant or biological relative of a participant, as follows:
• • Participant with a histologically confirmed breast cancer or other gynecologic malignancy; histopathology of the biopsy tissue must be
• • confirmed by the NCI Laboratory of Pathology, prior to banking of the tissue on this protocol.
• • Biological relative (1st 3rd degree) of a participant who meets the eligibility of histologically confirmed malignancy per above
• • criterion.
• • Subject willingness and ability to provide informed consent.
• • Subject willingness to provide tissue samples for banking.
• EXCLUSION CRITERIA:
• • - Pregnant individuals are not eligible to take part; pregnancy will be assessed using clinical criteria (medical history and physical exam).